An analysis of the DEA's proposed rescheduling of cannabis from Schedule I to Schedule III and its potential implications for cannabis businesses, financial institutions, and employers.
The FTC's final rule banning most non-compete agreements is facing significant legal challenges. We assess the current state of the rule and what employers should be doing now.
As generative AI tools proliferate across industries, courts and regulators are beginning to develop liability frameworks. We survey the emerging legal landscape and implications for companies deploying AI.
A review of recent federal appellate decisions addressing the scope of NLRA preemption of state and local labor regulations, with practical implications for employers operating across multiple jurisdictions.
The intersection of longevity science, AI-driven diagnostics, and health law raises novel regulatory questions. We examine FDA oversight, reimbursement considerations, and liability exposure for longevity medicine practitioners.